Page 3,035«..1020..3,0343,0353,0363,037..3,0403,050..»

National Hospital Network Launches Campaign to Educate Consumers about When to Choose Inpatient Rehabilitation vs. a …

Posted: Published on December 10th, 2014

HARRISBURG, Pa.--(BUSINESS WIRE)--Select Medical, one of the nations leading networks of inpatient rehabilitation hospitals, has launched an educational campaign to help consumers understand the benefits of an inpatient rehabilitation hospital vs. a nursing home. The campaign is entitled The Right Choice. The Right Setting. The Right Outcome. People who go to an inpatient rehabilitation hospital after they have had a serious stroke, brain injury, or spinal cord injury go home sooner, have a better quality of life, and live longer than patients who go to a nursing home, according to a Dobson DaVanzo & Associates study commissioned by the American Medical Rehabilitation Providers Association. Yet many Americans do not know what an inpatient rehabilitation hospital is, nor do they understand its value in treating neurological conditions and diseases, such as Parkinsons disease or multiple sclerosis. We want consumers to know that if they or a loved one ever have stroke, brain injury, spinal cord injury, or other neurological conditions, where they go to receive medical care and rehabilitation and how quickly they begin their treatment makes all the difference in the quality of their recovery, says Dr. Bruce M. Gans, Select Medicals national medical director for rehabilitation. For many people, … Continue reading

Posted in Brain Injury Treatment | Comments Off on National Hospital Network Launches Campaign to Educate Consumers about When to Choose Inpatient Rehabilitation vs. a …

Aridhia to take part in brain injury study

Posted: Published on December 10th, 2014

ARIDHIA, the health data analytics firm, has won funding to carry out a research project that could lead to improved detection and prediction in the early management of traumatic brain injuries. Edinburgh-based Aridhia, led by chief executive David Sibbald, will run the two-year study in collaboration with NHS Great Glasgow and Clyde, Philips Medical Systems UK and the University of Glasgow. Loading article content The study, which will take place at the Southern General Hospital, has been given the green light after public funding was secured through Innovate UK, the body formerly known as the Technology Strategy Board. Information on the level of funding provided and the overall cost of the project has not been disclosed. The project promises to introduce recent advances in big data modelling directly into clinical practice, which could ultimately lead to a better understanding of brain injuries. The collaborators hope that, by exploiting big data in a healthcare setting, clinicians will be able to make treatment decisions earlier, which in turn could lead to reduced hospital stays, in-hospital mortality and more cost-effective care. The project will see Aridhia deploy its AnalytiXagility software to store and analyse high frequency data collected from patients through bed-side monitoring … Continue reading

Posted in Brain Injury Treatment | Comments Off on Aridhia to take part in brain injury study

New Drug Development Alliance Formed To Tackle Multiple Sclerosis

Posted: Published on December 10th, 2014

By Suzanne Hodsden, contributing writer French-based pharmaceutical research company, Servier has invested an initial $47 million in GeNeuro for the development of GNbAC1, a biologic candidate undergoing testing as a multiple sclerosis (MS) therapy which currently in phase 2b testing. The treatment is the first of its kind and has the potential to revolutionize the ways that MS is clinically addressed. Under the terms of the agreement, Servier will finance phase 3 testing and global development costs. If the treatment proves successful, Servier has agreed to pay GeNeuro up to $480 million to reimburse sales milestones and future royalties. GNbAC1 is a humanized monoclonal antibody which targets MSRV-Env. According to GeNeuro, MSRV is typically latent but can be activated by certain outside triggers and viruses, such as Herpes or Epstein Barr. As a result, it expresses the envelope protein which instigates the progression of the disease. GeNeuro explains that scientists first discovered and isolated the MSRV-Env protein because it appeared in high concentrations in MS patients and correlated with the severity and progression of MS symptoms. GNbAC1 could potentially stop the progression of both relapsing remitting and progressive forms of MS by targeting the MSRV-Env protein without compromising a patients … Continue reading

Posted in MS Treatment | Comments Off on New Drug Development Alliance Formed To Tackle Multiple Sclerosis

Alice Lazzarini recounts both sides of the white coat

Posted: Published on December 10th, 2014

The cover of "Both Sides Now," written by Alice Lazzarini, a former Mount Tabor resident, about her experiences with Parkinsons disease. photo courtesy of Alice Lazzarini By Lisa Kintish In "Both Sides Now," Alice Lazzarini, a former Mount Tabor resident, details her journey from Parkinsons disease researcher to patient. She writes, "Before developing Parkinson disease, I was on the research team that identified the first gene to cause the disorder. Beyond this irony, Both Sides Now recounts my unique perspective from having been on both sides of the white coat." Upon being diagnosed with Parkinsons disease, Lazzarini, as is often the case with a diagnosis, went into denial. She said, "I did my best to chalk the evidence up to other things. Acceptance began to take hold once I realized that there was a story worth telling in the irony, and that I could turn it into a positive thing by speaking out in support of Parkinsons." It is said that knowledge is power, but knowing a great deal about the disease that is taking over one's body can have its pros and cons. Lazzarini said, "Because I knew the symptoms all too well, I actually diagnosed myself before seeking … Continue reading

Comments Off on Alice Lazzarini recounts both sides of the white coat

Thyroid Hormones Reduce Animal Cardiac Arrhythmias

Posted: Published on December 10th, 2014

Contact Information Available for logged-in reporters only Newswise Rats that received thyroid hormones had a reduced risk for dangerous heart arrhythmias following a heart attack, according to a new study by a team of medical researchers at New York Institute of Technology. In the NIH-funded study, published in the Journal of Cardiac Failure, the team found that thyroid hormone replacement therapy significantly reduced the incidence of atrial fibrillation a specific kind of irregular heartbeat, or arrhythmia -- in the rats, compared to a control group that did not receive the hormones. The finding could have important implications for future treatment of human patients, says lead researcher Youhua Zhang, MD, Ph.D., noting that up to about half of the humans with heart failure also suffer from atrial fibrillation. Our data highlights the potential clinical importance of correcting thyroid dysfunction to prevent cardiac arrhythmias and atrial fibrillation in heart failure, Zhang and the researchers wrote in their study. In other words, withholding thyroid hormone treatment in heart failure may do harm when cardiac hormone levels are below normal. Zhang said researchers induced heart attacks in a group of 29 rats. Fourteen were treated with a form of thyroid hormone known as T4. … Continue reading

Posted in Hormone Replacement Therapy | Comments Off on Thyroid Hormones Reduce Animal Cardiac Arrhythmias

BioTE Medical Joins Forever Health and National Spokesperson, Suzanne Somers

Posted: Published on December 10th, 2014

Dallas (PRWEB) December 09, 2014 Can optimal health be maintained while aging? Forever Health and their National Spokesperson, Suzanne Somers believes it can and they have a new ally in this work. As a part of their ongoing effort to raise the awareness among consumers and physicians about integrative medicine, Forever Health and Suzanne Somers the actress, singer, businesswoman, best-selling author, and the face of alternative healthcare have forged a strategic alliance with BioTE Medical, a national network of certified practitioners of bio-identical hormone replacement therapy (BHRT). Suzanne is the national spokesperson for Forever Health, a platform which allows patients to connect with qualified physicians who are trained in this innovative hormone balancing therapy. She noted, Thanks to BHRT, I enjoy robust health, balanced hormones, strong bones and the energy and vitality of someone half my age! BioTE Hormone Pellet Therapy is based on 34 years of research and relies on data and studies dating back as early as 1939, making this modality of therapy the longest-studied form of bio-identical hormone replacement therapy. BioTE Certified Practitioners use pellet therapy. This is the only form of hormone replacement therapy that ensures patient compliance 100% of the time, said Dr. Gary Donovitz, … Continue reading

Posted in Hormone Replacement Therapy | Comments Off on BioTE Medical Joins Forever Health and National Spokesperson, Suzanne Somers

Dr. Allens Device Boost Mens Wellbeing by Treating Enlarged Prostate & Chronic Prostatitis, While Testosterone …

Posted: Published on December 10th, 2014

London, GB (PRWEB) December 10, 2014 Men are now warned that testosterone replacement therapy (TRT) drugs are associated with a higher risk of cardiovascular problems such as heart attack, stroke, or deep vein thrombosis, highlights a recent article. Fine Treatment draws attention to the natural Thermobalancing therapy: men with symptoms of chronic prostatitis or prostate enlargement (BPH) may well avoid taking risky medications and improve their well-being by opting for a treatment with Dr. Allens Device for Prostate Care. The article, Side Effects Associated with Low T Prescription Drugs, dated December 4, 2014, in the Legal Examiner, says, many men that suffer from low testosterone (also known as Low T) are taking hormone replacement therapy drugs that are linked to serious health concerns including heart attack and stroke. However, the percentage of men 40 and older being treated for Low T increases. An article in the USA Today titled Popular low T therapy divides the medical field, of June 12, 2013, talks about a study in the JAMA Internal Medicine journal saying that the percentages of men 40 and older being treated for "Low T" more than tripled from 2001 to 2011. Meanwhile, doctors disagree about who should be treated … Continue reading

Posted in Hormone Replacement Therapy | Comments Off on Dr. Allens Device Boost Mens Wellbeing by Treating Enlarged Prostate & Chronic Prostatitis, While Testosterone …

This New Kind of Stem Cell May Revolutionize How We Treat Diseases

Posted: Published on December 10th, 2014

TIME Health medicine This New Kind of Stem Cell May Revolutionize How We Treat Diseases Scientists have created a new type of stem cell that could speed treatments for diseases and make them safer Ever since Japanese researcher Shinya Yamanaka found a way to treat skin cells with four genes and reprogram them back to their embryonic state, scientists have been buzzing over the promise of stem cell therapies. Stem cells can be coaxed to become any of the bodys cell types, so they could potentially replace diseased or missing cells in conditions such as diabetes or Alzheimers. And Yamanakas method also meant that these cells could be made from patients themselves, so they wouldnt trigger dangerous immune rejections. Now scientists led by Dr. Andras Nagy at Mount Sinai Hospital Lunenfeld-Tannenbaum Research Institute in Toronto report an exciting new advance that could push stem cells even closer to the clinic. In a series of papers in the journals Nature and Nature Communications, the group describes a new class of stem cell, which they called F class, that they generated in the lab. The F class cells, says Nagy, have a few advantages over the Yamanaka-generated induced pluripotent stem cells, or … Continue reading

Posted in Stem Cell Research | Comments Off on This New Kind of Stem Cell May Revolutionize How We Treat Diseases

NYSCF and the CMTA enter collaboration to advance neuropathies research

Posted: Published on December 10th, 2014

PUBLIC RELEASE DATE: 10-Dec-2014 Contact: David McKeon dmckeon@nyscf.org 212-365-7440 New York Stem Cell Foundation @nyscf New York, NY (December 10, 2014) - The New York Stem Cell Foundation (NYSCF) Research Institute, a non-profit organization dedicated to accelerating cures through stem cell research, announced a collaboration today with the Charcot-Marie-Tooth Association (CMTA), a patient-led disease foundation with the mission to advance research on genetic neuropathies that leads to the development of new therapies. The immediate aim of the collaboration is to develop a bank of induced pluripotent stem cell (iPSC) lines for a variety of neuropathy disorders of known genetic causation and to eventually develop personalized drug therapies. NYSCF will make stem cells lines from Charcot-Marie-Tooth patient materials that have been curated in a biobank assembled by Dr. Michael Shy at the University of Iowa, a member of the CMTA STAR consortium of sponsored investigators. Utilizing its automated technology, the NYSCF Global Stem Cell ArrayTM, NYSCF will systematically generate iPSC lines from tissue samples obtained from patients representing a number of disease states. These cell lines will then be used to develop methods for creating differentiated cells that mimic the myelin-producing Schwann cells that are defective in Type 1 Charcot-Marie-Tooth (CMT) … Continue reading

Posted in Stem Cell Research | Comments Off on NYSCF and the CMTA enter collaboration to advance neuropathies research

Pioneering Toronto scientists latest research to demystify stem cells

Posted: Published on December 10th, 2014

When Mount Sinai Hospital researcher Dr. Andras Nagy initiated a project to shine a light into the black box of turning specialized cells into stem cells, he wasnt expecting to find a whole new type of stem cell. Nagy says identifying a new class of stem cells means a 100 per cent increase in possible sources of cells for therapeutic use. He describes a stem cell as a blank tablet. They hold great potential to treat diseases that result from damaged tissue or loss of cells, such as Alzheimers, spinal cord injuries and blindness. His latest research, dubbed Project Grandiose because of its sheer scale, aimed to demystify the process by which specialized cells turn into stem cells. Nagy worked with a team of close to 50 researchers across four continents to document this process. These cells called induced pluripotent stem cells, or iPS cells can be used to form any type of cell in the body as an alternative to using the more controversial stem cells from embryos. The findings will be published Thursday in a package of papers in Nature and Nature Communications. The oldest example of a therapy based on stem calls is bone marrow transplants, which … Continue reading

Posted in Stem Cell Research | Comments Off on Pioneering Toronto scientists latest research to demystify stem cells

Page 3,035«..1020..3,0343,0353,0363,037..3,0403,050..»